Jacob Plieth, Senior Reporter from EP Vantage, reviewed decades development history of CAR-T therapy atopening remarks, pointed out the three keys to today CAR-T success:co-stimulated CARs, CD19 and B-cell malignancies, and "patient 1" inPenn's pediatric ALL study. Looks like we have come...
近日，皖南医学院第一附属医院（弋矶山医院）泌尿科和精准医学中心的部分研究人员在《International Immunopharmacology》期刊上发表了题目为 “Dominant negative TGFβ receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer”的研究论文。该研究发现DT-PSMA-CAR-T细...
On 18th October 2017, the USFDA authorized Axicabtagene ciloleucel, as a treatment for R/R diffuses large B-cell lymphoma (DL-BCL) and other uncommon large B-cell lymphomas(LBCL), which is the first approved CAR T-cell therapy in history [78]. On June 28th, 2018 the European ...
In this article, we have conducted a thorough review of the history and development of CAR-T cell therapy and outlined its high efficacy in the field of acute leukemia. It is believed that the combination of CAR-T cell therapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT)...
2023年12月,美国血液学会(ASH)第65届年会圆满结束,作为全球血液学领域的权威盛会之一,本次公布了多项CAR-T疗法的最新临床研究成果。 嵌合抗原受体-T(CAR-T)细胞疗法,自2017年获美国食品和药物管理局(FDA)批准以来,在白血病、多发性骨髓...
Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure of standard therapy (NCT04581473 and NCT03874897). In case 1, with CLDN 18.2 expression of 2+, 70%, 250×106cells we...
The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors are sti
2. Mitra, A., et al., From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol, 2023. 14: p. 1188049. 3. Merrill, J.T., et al., Efficacy and safety of rituximab in moderately-to-severely active systemic lupu...
期刊 :TRANSPLANTATION AND CELLULAR THERAPY 摘要：美国移植和细胞治疗学会（ASTCT）于2020年发布了其关于自体和异基因造血细胞移植（HCT）和免疫效应细胞治疗（IECT）的适应症指南。从那时起，我们见证了IECT领域的快速发展，导致了一些新的嵌合抗原受体t细胞（CAR-T）产品和疾病适应症得到了美国食品和药物管理局（FDA）...
[2]Mitra A,et al. From bench to bedside: the history and progress of CAR T cell therapy[J]. Frontiers in Immunology, 2023, 14: 1188049. https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188049/full [3]Giorgioni L,et al.CAR-T State of the Art and Future Challenges, A Regulato...